Chemed Corp
NYSE:CHE

  • LAST PRICE
    549.2700
  • TODAY'S CHANGE (%)
    8.3000 (1.5343%)
  • Bid / Lots
    533.5800/ 1
  • Ask / Lots
    558.3100/ 1
  • Open / Previous Close
    544.5600 / 540.9700
  • Day Range
    541.5300
    553.9500
  • 52 Week Range
    492.8400
    654.6200
  • Volume
    132,672

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Jul 24, 2024

      Show headlines and story abstract

    • 5:24PM ET on Wednesday Jul 24, 2024 by MT Newswires
      Companies Mentioned: CHE
      05:24 PM EDT, 07/24/2024 (MT Newswires) -- Chemed (CHE) reported Q2 adjusted earnings late Wednesday of $5.47 per diluted share, up from $4.08 a year earlier. Three analysts surveyed by Capital IQ expected $5.59. Revenue for the quarter ended June 3...

    • 4:25PM ET on Wednesday Jul 24, 2024 by MT Newswires
      Companies Mentioned: CHE
      04:25 PM EDT, 07/24/2024 (MT Newswires) -- ...

    • 4:25PM ET on Wednesday Jul 24, 2024 by MT Newswires
      Companies Mentioned: CHE
      04:25 PM EDT, 07/24/2024 (MT Newswires) -- ...

    • 4:15PM ET on Wednesday Jul 24, 2024 by Dow Jones
      Companies Mentioned: CHE
      CINCINNATI--(BUSINESS WIRE)--July 24, 2024--
      Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2024, versus the comparable prior-year period.

    • 4:15PM ET on Wednesday Jul 24, 2024 by Dow Jones
      Companies Mentioned: CHE
      ========= ========= ========= ========= Total Admissions 17,334 15,611 34,245 31,790 Total Discharges 15,898 15,104 32,068 30,509 Average length of stay (days) 100.6 99.5 102.2 99.7 Median length of stay (days) 18.0 16.0 17.0 15.0 ADC by major diagnosis Cerebro 42.5 % 41.9 % 43.4 % 42.0 % Neurological 13.3 18.8 13.4 19.0 Cancer 10.0 10.8 10.0 10.6 Cardio 16.2 16.1 16.2 16.0 Respiratory 7.3 7.1 7.3 7.2 Other 10.7 5.3 9.7 5.2 --------- --------- --------- --------- Total 100.0 % 100.0 % 100.0 % 100.0 % ========= ========= ========= ========= Admissions by major diagnosis Cerebro 27.1 % 25.9 % 27.4 % 26.2 % Neurological 8.3 10.1 7.9 10.4 Cancer 25.0 27.1 24.8 25.9 Cardio 16.1 16.3 15.9 16.3 Respiratory 9.6 9.8 10.1 10.4 Other 13.9 10.8 13.9 10.8 --------- --------- --------- --------- Total 100.0 % 100.0 % 100.0 % 100.0 % ========= ========= ========= ========= Estimated uncollectible accounts as a percent of revenues 1.0 % 1.0 % 1.1 % 1.0 % Accounts receivable -- Days of revenue outstanding-excluding unapplied Medicare payments 38.8 35.2 n.a. n.a. Days of revenue outstanding-including unapplied Medicare payments 34.7 22.6 n.a. n.a. The "Footnotes to Financial Statements" are integral parts of this financial information. CHEMED CORPORATION AND SUBSIDIARY COMPANIES FOOTNOTES TO FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (unaudited) Included in the results of operations for 2024 are the following significant credits/(charges) which may not be indicative of ongoing (a) operations (in thousands): Three Months Ended June 30, 2024 ---------------------------------------------------- VITAS Roto-Rooter Corporate Consolidated ------ --------------- --------- ---------------- Stock option expense $ - $ - $ (8,870) $ (8,870) Long-term incentive compensation - - (3,593) (3,593) Amortization of reacquired franchise agreements - (2,352) - (2,352) Acquisition expense (907) (45) - (952) ---- ------- ------- -------- Pretax impact on earnings (907) (2,397) (12,463) (15,767) Excess tax benefits on stock compensation - - 622 622 Income tax benefit on the above 220 559 1,834 2,613 ---- ------- ------- -------- After-tax impact on earnings $(687) $ (1,838) $(10,007) $ (12,532) ==== ======= ======= ======== Six Months Ended June 30, 2024 ---------------------------------------------------- VITAS Roto-Rooter Corporate Consolidated ------ --------------- --------- ---------------- Stock option expense $ - $ - $(17,895) $ (17,895) Long-term incentive compensation - - (7,377) (7,377) Severance arrangement - - (5,337) (5,337) Amortization of reacquired franchise agreements - (4,704) - (4,704) Acquisition expense (907) (45) - (952) ---- ------- ------- -------- Pretax impact on earnings (907) (4,749) (30,609) (36,265) Excess tax benefits on stock compensation - - 3,919 3,919 Income tax benefit on the above 220 1,107 3,673 5,000 ---- ------- ------- -------- After-tax impact on earnings $(687) $ (3,642) $(23,017) $ (27,346) ==== ======= ======= ======== Included in the results of operations for 2023 are the following significant credits/(charges) which may not be indicative of ongoing (b) operations (in thousands): Three Months Ended June 30, 2023 ---------------------------------------------------- VITAS Roto-Rooter Corporate Consolidated ------ --------------- --------- ---------------- Stock option expense $ - $ - $ (8,400) $ (8,400) Amortization of reacquired franchise agreements - (2,352) - (2,352) Long-term incentive compensation - - (1,750) (1,750) ---- ------- ------- -------- Pretax impact on earnings - (2,352) (10,150) (12,502) Excess tax benefits on stock compensation - - 1,501 1,501 Income tax benefit on the above - 623 1,643 2,266 ---- ------- ------- -------- After-tax impact on earnings $ - $ (1,729) $ (7,006) $ (8,735) ==== ======= ======= ======== Six Months Ended June 30, 2023 ---------------------------------------------------- VITAS Roto-Rooter Corporate Consolidated ------ --------------- --------- ---------------- Stock option expense $ - $ - $(16,882) $ (16,882) Amortization of reacquired franchise agreements - (4,704) - (4,704) Long-term incentive compensation - - (4,264) (4,264) Litigation settlements - (1,756) - (1,756) ---- ------- ------- -------- Pretax impact on earnings - (6,460) (21,146) (27,606) Excess tax benefits on stock compensation - - 3,150 3,150 Income tax benefit on the above - 1,712 3,406 5,118 ---- ------- ------- -------- After-tax impact on earnings $ - $ (4,748) $(14,590) $ (19,338) ==== ======= ======= ======== (c) VITAS has 10 large (greater than 450 ADC), 22 medium (greater than 200 but less than 450 ADC) and 21 small (less than 200 ADC) hospice programs. Of Vitas' 32 Medicare provider numbers, for the trailing 12 months, 28 provider numbers have a Medicare cap cushion of greater than 10%, one provider number has a Medicare cap cushion between 5% and 10%, two provider numbers has a Medicare cap cushion between 0% and 5%, and one provider number has a Medicare cap liability.

Peers Headlines